These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247 [TBL] [Abstract][Full Text] [Related]
25. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS; Schellhammer PF J Urol; 2007 Dec; 178(6):2314-30. PubMed ID: 17993339 [No Abstract] [Full Text] [Related]
26. Invasive bladder cancer--where do we go from here? Waters WB J Urol; 1996 Jun; 155(6):1910-1. PubMed ID: 8618285 [No Abstract] [Full Text] [Related]
27. Management of transitional cell carcinoma of the bladder. Murshidi MS Arch Esp Urol; 1989 Mar; 42(2):172-5. PubMed ID: 2735783 [TBL] [Abstract][Full Text] [Related]
28. The role of endoscopic treatment after radical radiotherapy for invasive bladder cancer. Smith G; Quilty PM; Duncan W; Chisholm GD; Newsam JE; Hargreave TB Br J Urol; 1985 Dec; 57(6):694-9. PubMed ID: 4084728 [TBL] [Abstract][Full Text] [Related]
29. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Scher HI J Urol; 1994 Aug; 152(2 Pt 1):574-5. PubMed ID: 8015114 [No Abstract] [Full Text] [Related]
31. Coincident vesical transitional cell carcinoma and prostatic carcinoma. Clinical features and treatment. Androulakakis PA; Schneider HM; Jacobi GH; Hohenfellner R Br J Urol; 1986 Apr; 58(2):153-6. PubMed ID: 3697629 [TBL] [Abstract][Full Text] [Related]
32. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
33. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266 [TBL] [Abstract][Full Text] [Related]
34. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637 [TBL] [Abstract][Full Text] [Related]
35. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 64 patients. Montie JE J Urol; 2005 Jun; 173(6):1920-1. PubMed ID: 15879778 [No Abstract] [Full Text] [Related]
36. Transurethral surgery in the treatment of invasive bladder cancer (T1 and T2). Wolf H; Iversen HG; Rosenkilde P; Schrøder T Scand J Urol Nephrol Suppl; 1987; 104():127-32. PubMed ID: 3481460 [TBL] [Abstract][Full Text] [Related]
37. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies. Zhang M; Tao R; Zhang C; Shen Z Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377 [TBL] [Abstract][Full Text] [Related]
38. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. Solsona E; Iborra I; Rubio J; Casanova J; Almenar S BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101 [TBL] [Abstract][Full Text] [Related]
39. [Infiltrating transitional carcinoma of the bladder (4). Our approach to stage pT2 and critique of other risk factors. Multifactorial analysis]. Escudero Barrilero A; Perales L; Romero J; Rodríguez Luna JM; Vallejo J; Rivas JA Actas Urol Esp; 1991; 15(5):411-20. PubMed ID: 1807119 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]